Across 16 randomized controlled trials enrolling 6,611 adults with cardiometabolic disease, dual GLP-1 receptor and glucagon receptor (GCGR) agonists produced a placebo-corrected body weight reduction of 7.44% (−7.27 kg, 95% CI −9.28 to −5.27), accompanied by improvements in waist circumference, total cholesterol, LDL, triglycerides, HbA1c, and hemodynamic markers. Critically, head-to-head comparison against selective GLP-1R agonists revealed a meaningful additional triglyceride reduction of −0.28 mmol/L, suggesting the glucagon receptor arm contributes distinct metabolic signaling beyond weight loss alone.
The glucagon receptor has long been understood to drive hepatic fat oxidation and thermogenesis — mechanisms that complement GLP-1's incretin and satiety effects. This meta-analysis is the most comprehensive synthesis to date of dual-agonist RCT data, and the triglyceride finding is clinically meaningful: hypertriglyceridemia remains an underappreciated residual cardiovascular risk factor even after LDL control. The −0.28 mmol/L difference, while modest in absolute terms, could translate to meaningful atherosclerotic risk reduction at population scale, particularly in patients with mixed dyslipidemia or metabolic-associated fatty liver disease.
Limitations are significant: treatment durations varied (minimum 12 weeks), cardiovascular hard outcomes were not assessed, and the included compounds — several still in development — differ considerably in receptor selectivity ratios. This is a meta-analysis of surrogate endpoints, not events. Still, the consistency across risk factor domains is compelling. The finding is best characterized as confirmatory-plus — it validates the dual-agonist class while adding a specific mechanistic advantage signal that warrants dedicated outcomes trials.